nach oben

Erschienen in:

27.01.2024 | Original Article

Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells

verfasst von: Alexandr N. Chernov, Alexandr V. Kim, Sofia S. Skliar, Evgeniy V. Fedorov, Anna N. Tsapieva, Tatiana A. Filatenkova, Aleksei L. Chutko, Marina V. Matsko, Elvira. S. Galimova, Olga V. Shamova

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Objective

Glioblastoma multiforme (GBM) is the most aggressive and fatal malignant primary brain tumor. The enhancement of the survival rate for glioma patients remains limited, even with the utilization of a combined treatment approach involving surgery, radiotherapy, and chemotherapy. This study was designed to assess the expression of IDH1, TP53, EGFR, Ki-67, GFAP, H3K27M, MGMT, VEGF, NOS, CD99, and ATRX in glioblastoma tissue from 11 patients. We investigated the anticancer impact and combined effects of cathelicidin (LL-37), protegrin-1 (PG-1), with chemotherapy—temozolomide (TMZ), doxorubicin (DOX), carboplatin (CB), cisplatin (CPL), and etoposide (ETO) in primary GBM cells. In addition, we examined the effect of LL-37, PG-1 on normal human fibroblasts and in the C6/Wistar rat intracerebral glioma model.

Methods

For this study, 11 cases of glioblastoma were evaluated immunohistochemically for IDH1, TP53, EGFR, Ki-67, GFAP, H3K27M, MGMT, VEGF, NOS, CD99, and ATRX. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to study cells viability and to determine cytotoxic effects of LL-37, PG-1 and their combination with chemotherapy in primary GBM cells. Synergism or antagonism was determined using combination index (CI) method. Finally, we established C6 glioblastoma model in Wistar rats to investigate the antitumor activity.

Results

Peptides showed a strong cytotoxic effect on primary GBM cells in the MTT test (IC₅₀ 2–16 and 1–32 μM) compared to chemotherapy. The dual-drug combinations of LL-37 + DOX, LL-37 + CB (CI 0.46–0.75) and PG-1 + DOX, PG-1 + CB, PG-1 + TMZ (CI 0.11–0.77), demonstrated a synergism in primary GBM cells. In rat C6 intracerebral GBM model, survival of rats in experimental group (66.75 ± 12.6 days) was prolonged compared with that in control cohort (26.2 ± 2.66 days, p = 0.0008). After LL-37 treatment, experimental group rats showed significantly lower tumor volumes (31.00 ± 8.8 mm³) and weight (49.4 ± 13.3 mg) compared with control group rats (153.8 ± 43.53 mg, p = 0.038; 82.50 ± 7.60 mm³, respectively).

Conclusions

The combination of antimicrobial peptides and chemical drugs enhances the cytotoxicity of chemotherapy and exerts synergistic antitumor effects in primary GBM cells. Moreover, in vivo study provided the first evidence that LL-37 could effectively inhibit brain tumor growth in rat C6 intracerebral GBM model. These results suggested a significant strategy for proposing a promising therapy for the treatment of GBM.

Graphical Abstract

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU (2017) Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev 18(1):3–9PubMedPubMedCentral

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1CrossRefPubMed

Jeon J, Lee S, Kim H, Kang H, Youn HS, Jo S, Youn BH, Kim HY (2021) Revisiting platinum-based anticancer drugs to overcome gliomas. Int J Mol Sci 22(10):5111CrossRefPubMedPubMedCentral

Leonard A, Wolff JE (2013) Etoposide improves survival in high-grade glioma: a meta-analysis. Anticancer Res 33(8):3307–3315PubMed

Abou-Antoun TJ, Hale JS, Lathia JD, Dombrowski SM (2017) Brain cancer stem cells in adults and children: cell biology and therapeutic implications. Neurotherapeutics 14:372–384. https://doi.org/10.1007/s13311-017-0524-0CrossRefPubMedPubMedCentral

Olivier Ch, Oliver L, Lalier L, Vallette FM (2021) Drug resistance in glioblastoma: the two faces of oxidative stress. Front Mol Biosci 7:620677. https://doi.org/10.3389/fmolb.2020.620677CrossRefPubMedPubMedCentral

Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068. https://doi.org/10.1038/nature07385CrossRef

Zhao Z, Zhang KN, Wang Q, Li G, Zeng F, Zhang Y, Wu F, Chai R, Wang Z, Zhang C, Zhang W, Bao Z, Jiang T (2021) Chinese Glioma Genome Atlas (CGGA): a comprehensive resource with functional genomic data for Chinese glioma patients. Genom Proteom Bioinf 19(1):1–12. https://doi.org/10.1016/j.gpb.2020.10.005CrossRef

10.

Zhang P, Xia Q, Liu L, Li S, Dong L (2020) Current opinion on molecular characterization for GBM classification in guiding clinical diagnosis, prognosis, and therapy. Front Mol Biosci 7:562798. https://doi.org/10.3389/fmolb.2020.562798CrossRefPubMedPubMedCentral

11.

Ye G, Wu H, Huang J, Huang J, Wang W, Ge K, Li G, Zhong J, Huang Q (2020) LAMP2: a major update of the database linking antimicrobial peptides. Database. https://doi.org/10.1093/database/baaa061CrossRefPubMedPubMedCentral

12.

Büyükkiraz ME, Kesmen Z (2022) Antimicrobial peptides (AMPs): a promising class of antimicrobial compounds. J Appl Microbiol 132(3):1573–1596. https://doi.org/10.1111/jam.15314CrossRef

13.

Wnorowska U, Fiedoruk K, Piktel E, Prasad SV, Sulik M, Janion M, Daniluk T, Savage PB, Bucki R (2020) Nanoantibiotics containing membrane-active human cathelicidin LL-37 or synthetic ceragenins attached to the surface of magnetic nanoparticles as novel and innovative therapeutic tools: current status and potential future applications. J Nanobiotechnol 18:3. https://doi.org/10.1186/s12951-019-0566-zCrossRef

14.

Kuroda K, Okumura K, Isogai H, Isogai E (2015) The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs. Front Oncol 5:144. https://doi.org/10.3389/fonc.2015.00144CrossRefPubMedPubMedCentral

15.

Chernov AN, Tsapieva AN, Alaverdian DA, Filatenkova TA, Galimova ES, Suvorova M, Shamova OV, Suvorov AN (2022) In vitro evaluation of cytotoxic effect of Streptococcus pyogenes strains, Protegrin PG-1, Cathelicidin LL-37, Nerve Growth Fac-tor and chemotherapy on C6 glioma cell line. Molecules 27(2):569. https://doi.org/10.3390/molecules27020569CrossRefPubMedPubMedCentral

16.

Chernov A, Filatenkova T, Glushakov RI, Buntovskaya AS, Alaverdian DA, Tsapieva AN, Kim AV, Fedorov EV, Skliar SS, Matsko MV, Galimova ES, Shamova OV (2022) Anticancer effect of cathelicidin LL-37, protegrin PG-1, nerve growth factor NGF, and temozolomide: impact on the mitochondrial metabolism, clonogenic potential, and migration of human U251 glioma cells. Molecules 27:4988. https://doi.org/10.3390/molecules27154988CrossRefPubMedPubMedCentral

17.

Chen X, Zou X, Qi G, Tang Y, Guo Y, Si J, Liang L (2018) Roles and mechanisms of human cathelicidin LL-37 in cancer. Cell Physiol Biochem 47(3):1060–1073. https://doi.org/10.1159/000490183CrossRefPubMed

18.

Tzitzilis A, Boura-Theodorou A, Michail V, Papadopoulos S, Krikorian D, Lekka ME, Koukkou AI, Sakarellos-Daitsiotis M, Panou-Pomonis E (2020) Cationic amphipathic peptide analogs of cathelicidin LL-37 as a probe in the development of antimicrobial/anticancer agents. J Pept Sci 26(7):e3254. https://doi.org/10.1002/psc.3254CrossRefPubMed

19.

Rothan HA, Mohamed Z, Sasikumar PG, Reddy KA, Rahman NA, Yusof R (2014) In vitro characterization of novel protegrin-1 analogues against neoplastic cells. Intern J Peptide Res Ther 20(3):259–267. https://doi.org/10.1007/s10989-013-9388-2CrossRef

20.

Zharkova MS, Artamonov AYu, Grinchuk TM et al (2016) Peptides of the innate immune system modulate the cytotoxic effect of antitumor antibiotics. Ross Immunolog J 10(2):548–550

21.

Soundrarajan N, Park S, Le Van Q, Chanh C-S, Raghunathan G, Ahn B, Song H, Kim J-H, Park C (2019) Protegrin-1 cytotoxicity towards mammalian cells positively correlates with the magnitude of conformational changes of the unfolded form upon cell interaction. Sci Rep 9:11569. https://doi.org/10.1038/s41598-019-47955-2CrossRefPubMedPubMedCentral

22.

Shamova OV, Orlov DS, Pazina TY et al (2012) Study of the molecular and cellular bases of the cytotoxic effect of antimicrobial peptides on tumor cells. Fundamental Res 5:207–212

23.

Lei J, Sun L, Huang S, Zhu C, Li P, He J, Mackey V, Coy DH, He Q (2019) The antimicrobial peptides and their potential clinical applications. Am J Transl Res 11(7):3919–3931PubMedPubMedCentral

24.

Cheng F, Wan X, Wang B, Li Y, Peng P, Xu S, Han C, Mao F, Guo D (2022) Establishment and characteristics of GWH04, a new primary human glioblastoma cell line. Int J Oncol 61(5):139. https://doi.org/10.3892/ijo.2022.5429CrossRefPubMedPubMedCentral

25.

Amini S, White MK (2013) Neuronal cell culture. methods and protocols. Humana, TotowaCrossRef

26.

Brem H, Golinko MS, Stojadinovic O, Kodra A, Diegelmann RF, Vukelic S, Entero H, Coppock DL, Tomic-Canic M (2008) Primary cultured fibroblasts derived from patients with chronic wounds: a methodology to produce human cell lines and test putative growth factor therapy such as GMCSF. J Transl Med 6:75. https://doi.org/10.1186/1479-5876-6-75CrossRefPubMedPubMedCentral

27.

Riss TL, Moravec RA, Niles AL et al (2013) Assay Guidance Manual Cell Viability Assays. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda

28.

Junka AF, Janczura A, Smutnicka D, Mączyńska B, Anna S, Nowicka J, Bartoszewicz M, Gościniak G (2012) Use of the real time xCELLigence system for purposes of medical microbiology. Pol J Microbiol 61:191–197CrossRefPubMed

29.

Chou T-C (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621–681. https://doi.org/10.1124/pr.58.3.10CrossRefPubMed

30.

Takano S, Kato Y, Yamamoto T, Kaneko MK, Ishikawa E, Tsujimoto Y, Matsuda M, Nakai K, Yanagiya R, Morita S, Tsuboi K, Matsumura A (2012) Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol 108:361–373. https://doi.org/10.1007/s11060-012-0837-0CrossRefPubMed

31.

Abdulghani MM, Abbas MN, Mohammed WR (2019) Immunohistochemical expression of epidermal growth factor receptor in astrocytic tumors in Iraqi patients. Open Access Maced J Med Sci 7(21):3514–3520. https://doi.org/10.3889/oamjms.2019.751CrossRefPubMedPubMedCentral

32.

Takano S, Ishikawa E, Sakamoto N, Matsuda M, Akutsu H, Noguchi M, Kato Y, Yamamoto T, Matsumura A (2016) Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. Brain Tumor Pathol 33(2):107–116. https://doi.org/10.1007/s10014-016-0260-xCrossRefPubMed

33.

Brehar FM, Arsene D, Gorgan BLA, MR. (2015) Immunohistochemical analysis of GFAP-δ and nestin in cerebral astrocytomas. Brain Tumor Pathol 32(2):90–98. https://doi.org/10.1007/s10014-014-0199-8CrossRefPubMed

34.

Seol HJ, Chang JH, Yamamoto J, Romagnuolo R, Suh Y, Weeks A, Agnihotri S, Smith CA, Rutka JT (2012) Overexpression of CD99 increases the migration and invasiveness of human malignant glioma cells. Genes Cancer 3(9–10):535–549. https://doi.org/10.1177/1947601912473603CrossRefPubMedPubMedCentral

35.

Morelatto R, Itoiz ME, Guiñazú N, Piccini D, Gea S, López-de BS (2014) Nitric oxide synthase 2 (NOS2) expression in histologically normal margins of oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 19(3):e242–e247. https://doi.org/10.4317/medoral.19351CrossRefPubMed

36.

Huang T, Garcia R, Qi J, Lulla R, Horbinski C, Behdad A, Wadhwani N, Shilatifard A, James C, Saratsis AM (2018) Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes. Oncotarget 9(98):37112–37124. https://doi.org/10.18632/oncotarget.26430CrossRefPubMedPubMedCentral

37.

Loureiro LVM, Neder L, Callegaro-Filho D, Stavale JN, Fleury Malheiros SM (2020) The immunohistochemical landscape of the VEGF family and its receptors in glioblastomas. Surg Exp Pathol 3:9. https://doi.org/10.1186/s42047-020-00060-5CrossRef

38.

van Belle G, Fisher LD, Heagerty PJ et al (2004) Biostatistics: a methodology for the health sciences. Jonh Wiley and Sons Inc, HobokenCrossRef

39.

Fittipaldi A, Ferrari A, Zoppe M, Arcangeli C, Pellegrini V, Beltram F, Giacca M (2003) Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 278:34141–34149CrossRefPubMed

40.

Filewod NCJ, Pistolic J, Hancock REW (2009) Low concentrations of LL-37 alter IL-8 production by keratinocytes and bronchial epithelial cells in response to proinflammatory stimuli. FEMS Immunol Med Microbiol 56(3):233–240. https://doi.org/10.1111/j.1574-695X.2009.00571.xCrossRefPubMed

41.

Ren SX, Shen J, Cheng ASL, Lu L, Chan RLY et al (2015) Correction: FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS ONE 10(6):e0131750. https://doi.org/10.1371/journal.pone.0131750CrossRefPubMedPubMedCentral

42.

Wewers MD, Sarkar A (2009) P2X7 receptor and macrophage function. Purinergic Signal 5(2):189–195. https://doi.org/10.1007/s11302-009-9131-9CrossRefPubMedPubMedCentral

43.

Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang Y-H, Su B, Nestle FO et al (2007) Plasmacytoid dendritic cells sense self-DNA coupled with anti-microbial peptide. Nature 449(7162):564–569. https://doi.org/10.1038/nature06116CrossRefPubMed

44.

Lee M, Shi X, Barron AE, McGeer E, McGeer PL (2015) Human antimicrobial peptide LL-37 induces glial-mediated neuroinflammation. Biochem Pharmacol 94(2):130–141. https://doi.org/10.1016/j.bcp.2015.02.003CrossRefPubMed

45.

Piktel E, Niemirowicz K, Wnorowska U, Wątek M, Wollny T, Głuszek K, Góźdź S, Levental I, Bucki R (2016) The role of cathelicidin LL-37 in cancer development. Arch Immunol Ther Exp 64:33–46. https://doi.org/10.1007/s00005-015-0359-5CrossRef

46.

Colle J-H, Périchon B, Garcia A (2019) Antitumor and antibacterial properties of virally encoded cationic sequences. Biologics 3:117–126. https://doi.org/10.2147/BTT.S201287CrossRef

47.

Wang J, Cheng M, Law IKM, Ortiz C, Sun M, Koon HW (2019) Cathelicidin suppresses colon cancer metastasis via a P2RX7-dependent mechanism. Mol Ther Oncolytics 12:195–203. https://doi.org/10.1016/j.omto.2019.01.004CrossRefPubMedPubMedCentral

48.

Chen K, Gong W, Huang J, Yoshimura T, Wang JM (2021) The potentials of short fragments of human anti-microbial peptide LL-37 as a novel therapeutic modality for diseases. Front Biosci 26(11):1362–1372. https://doi.org/10.52586/5029CrossRef

49.

Wu WK, Sung JJ, To KF, Yu L, Li HT, Li ZJ, Chu KM, Yu J, Cho CH (2010) The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells. J Cell Physiol 223:178–186CrossRefPubMed

50.

Choi KY, Napper S, Mookherjee N (2014) Human cathelicidin LL-37 and its derivative IG-19 regulate interleukin-32-induced inflammation. Immunology 143:68–80. https://doi.org/10.1111/imm.12291CrossRefPubMedPubMedCentral

51.

Korhonen R, Moilanen E (2014) Mitogen-activated protein kinase phosphatase 1 as an inflammatory factor and drug target. Basic Clin Pharmacol Toxicol 114:24–36. https://doi.org/10.1111/bcpt.12141CrossRefPubMed

52.

Neto GTC, de Lima TM, Barbeiro HV, Chammas R, Machado MCC, Pinheiro da Silva F (2016) Cathelicidin LL-37 promotes or inhibits cancer cell stemness depending on the tumor origin. Oncomedicine 1:14–17. https://doi.org/10.7150/oncm.16802CrossRef

53.

Zhang H, Zhen J, Zhang R, Wanyan Y, Liu K, Yuan X, Tao L, Chen Y (2022) Cathelicidin hCAP18/LL-37 promotes cell proliferation and suppresses antitumor activity of 1,25(OH)2D3 in hepatocellular carcinoma. Cell Death Discov 8:27. https://doi.org/10.1038/s41420-022-00816-wCrossRefPubMedPubMedCentral

54.

Can G, Akpinar B, Baran Y, Zhivotovsky B, Olsson M (2013) 5-Fluorouracil signaling through a calcium–calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. Oncogene 32(38):4529–4538. https://doi.org/10.1038/onc.2012.467CrossRefPubMed

55.

Yan HX, Wu HP, Zhang HL, Ashton C, Tong C, Wu J, Qian Q-J, Wang H-Y, Ying Q-L (2013) DNA damage-induced sustained p53 activation contributes to inflammation-associated hepatocarcinogenesis in rats. Oncogene 32(38):4565–4571. https://doi.org/10.1038/onc.2012.451CrossRefPubMed

56.

Elssner A, Duncan M, Gavrilin M, Wewers MD (2004) A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 172:4987–4994. https://doi.org/10.4049/jimmunol.172.8.4987CrossRefPubMed

57.

Skaper SD, Debetto P, Giusti P (2010) The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J 24(2):337–345. https://doi.org/10.1096/fj.09-138883CrossRefPubMed

58.

Koczulla R, von Degenfeld G, Kupatt C, Krötz F, Zahler S, Gloe T, Issbrücke K, Unterberger P, Zaiou M, Lebherz C et al (2003) An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 111(11):1665–1672. https://doi.org/10.1172/JCI17545CrossRefPubMedPubMedCentral

59.

Nagaoka I, Tamura H, Hirata M (2006) An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. J Immunol 176:3044–3052. https://doi.org/10.4049/jimmunol.176.5.3044CrossRefPubMed

60.

Rao NM (1992) Differential susceptibility of phosphatidylcholine small unilamellar vesicles to phospholipases A2, C and D in the presence of membrane active peptides. Biochem Biophys Res Commun 182(2):682–688. https://doi.org/10.1016/0006-291x(92)91786-pCrossRefPubMed

61.

Ohtsu H, Dempsey PJ, Eguchi S (2006) ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 291(1):C1-10. https://doi.org/10.1152/ajpcell.00620.2005CrossRefPubMed

62.

Radic M, Muller S (2022) LL-37, a multi-faceted amphipathic peptide involved in NETosis. Cells 11(15):2463. https://doi.org/10.3390/cells11152463CrossRefPubMedPubMedCentral

63.

Sak M, Zumbar CT, King PD, Li X, Mifsud CS, Usubalieva A et al (2019) Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells. J Neurooncol 143(2):231–240. https://doi.org/10.1007/s110CrossRefPubMedPubMedCentral

64.

LuY KJ, Liu Y, Tech K, Frady LN, Su Y-T, Bautista W, In Moon S, MacDonald J, Ewend MG, Gilbert MR, Yang C, Wu J (2017) Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repair. Cancer Res 77(7):1709–1718. https://doi.org/10.1158/0008-5472.CAN-16-2773CrossRef

65.

Lin L, Cai J, Tan Z, Meng X, Li R, Li Y, Jiang C (2021) Mutant IDH1 enhances temozolomide sensitivity via regulation of the ATM/CHK2 pathway in glioma. Cancer Res Treat 53(2):367–377. https://doi.org/10.4143/crt.2020.506CrossRefPubMed

66.

Hermawan A, Wulandari F, Hanif N, Utomo RY, Jenie RI, Ikawati M, Tafrihani AS (2022) Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment integrated computational analysis and in vitro study. Sci Rep 12:13928. https://doi.org/10.1038/s41598-022-18348-9CrossRefPubMedPubMedCentral

67.

Lipp ES, Healy P, Austin A, Clark A, Dalton T, Perkinson K, Herndon JE, Friedman HS, Friedman AH, Bigner DD, McLendon RE (2019) MGMT: immunohistochemical detection in high-grade astrocytomas. J Neuropathol Exp Neurol 78(1):57–64. https://doi.org/10.1093/jnen/nly110CrossRefPubMed

68.

Butler M, Pongor L, Su Y-T, Xi L, Raffeld M, Quezado M, Trepel J, Aldape K, Pommier Y, Wu J (2020) MGMT status as a clinical biomarker in glioblastoma. Trends Cancer 6(5):380–391. https://doi.org/10.1016/j.trecan.2020.02.010CrossRefPubMedPubMedCentral

69.

Szylberg M, Sokal P, Sledzinska P, Bebyn M, Krajewski S, Szylberg Ł et al (2022) MGMT promoter methylation as a prognostic factor in primary glioblastoma: a single institution observational study. Biomedicines 10:2030. https://doi.org/10.3390/biomedicines10082030CrossRefPubMedPubMedCentral

Titel: Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells
verfasst von: Alexandr N. Chernov
Alexandr V. Kim
Sofia S. Skliar
Evgeniy V. Fedorov
Anna N. Tsapieva
Tatiana A. Filatenkova
Aleksei L. Chutko
Marina V. Matsko
Elvira. S. Galimova
Olga V. Shamova
Publikationsdatum: 27.01.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 5/2024
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-023-04622-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells